Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119831
Chunk: 171

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 171
---
 research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, acquisitions of new technologies and investments, business
combinations and the repayment, refinancing, redemption or repurchase of indebtedness or capital stock, although we believe we can fund our operations with cash on hand and from additional sources of financing that we may seek from time to
time.However, we have not designated any specific uses and have no current agreement with respect to any acquisition or strategic transaction. As of the date of this prospectus, we cannot specify with certainty all of the particular
uses, and the respective amounts we may allocate to those uses, for any proceeds we receive from the exercise of the Penny Warrants. Accordingly, we will retain broad discretion over the use of these proceeds. Pending our use of the proceeds as
described above, we intend to invest such proceeds in interest-bearing instruments. There is no assurance that the holders of the Penny Warrants will elect to exercise any or all of such Penny Warrants. To the extent that the Penny Warrants are
exercised on a “cashless basis,” the amount of cash we would receive from the exercise of the Penny Warrants will decrease.

105

DETERMINATION OF OFFERING PRICE

We cannot currently determine the price or prices at which shares of our Common Stock may be sold by the Selling Stockholder under this
prospectus.

106

MARKET INFORMATION FOR SECURITIES AND DIVIDEND POLICY

Market Information

Our Common Stock and
Public Warrants are currently listed on Nasdaq under the symbols “SCLX” and “SCLXW,” respectively. Prior to the consummation of the Business Combination, Vickers’s Ordinary Shares, units and warrants were each listed on
Nasdaq under the symbols “VCKA,” “VCKAU” and “VCKAW,” respectively. At the Effective Time, without any action on the part of the holder, each Unit then outstanding separated automatically into its component securities,
comprised of one share of Common Stock and one-half of one warrant to purchase one share of Common Stock. As of March 31, 2025 and taking into account the effect of the Reverse Stock Split, there were 244
holders of record of our Common Stock and one holder of record of our Public Warrants, which amount does not include participants of The Depository Trust Company or beneficial owners holding shares through nominee names.

Dividend Policy

Except as set forth
below, we have never declared or paid any dividend